Join
Live feed
·
INSIDERFilingvia Quantisnow
Arcus Biosciences Inc. logo

Chief Financial Officer Goeltz Ii Robert C. sold $198,966 worth of shares (7,763 units at $25.63) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 84,161 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RCUS· Arcus Biosciences Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RCUS (Arcus Biosciences Inc.) and more on Quantisnow.